nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivastigmine—BCHE—Cisplatin—urinary bladder cancer	0.178	0.51	CbGbCtD
Rivastigmine—CYP3A4—Thiotepa—urinary bladder cancer	0.0983	0.281	CbGbCtD
Rivastigmine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0286	0.0817	CbGbCtD
Rivastigmine—CYP3A4—Etoposide—urinary bladder cancer	0.0267	0.0761	CbGbCtD
Rivastigmine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0182	0.0519	CbGbCtD
Rivastigmine—Tapentadol—UGT2B7—urinary bladder cancer	0.0119	1	CrCbGaD
Rivastigmine—CYP2D6—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00314	0.077	CbGpPWpGaD
Rivastigmine—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00205	0.0503	CbGpPWpGaD
Rivastigmine—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00204	0.0501	CbGpPWpGaD
Rivastigmine—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00171	0.0419	CbGpPWpGaD
Rivastigmine—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00145	0.0356	CbGpPWpGaD
Rivastigmine—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00118	0.0288	CbGpPWpGaD
Rivastigmine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00107	0.0263	CbGpPWpGaD
Rivastigmine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.000948	0.0232	CbGpPWpGaD
Rivastigmine—ACHE—prostate gland—urinary bladder cancer	0.000914	0.17	CbGeAlD
Rivastigmine—ACHE—Peptide hormone metabolism—CDX2—urinary bladder cancer	0.000875	0.0215	CbGpPWpGaD
Rivastigmine—CYP3A4—urine—urinary bladder cancer	0.000842	0.157	CbGeAlD
Rivastigmine—ACHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—urinary bladder cancer	0.000842	0.0206	CbGpPWpGaD
Rivastigmine—CYP2D6—urine—urinary bladder cancer	0.000829	0.154	CbGeAlD
Rivastigmine—BCHE—Peptide hormone metabolism—CDX2—urinary bladder cancer	0.000781	0.0192	CbGpPWpGaD
Rivastigmine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000769	0.0189	CbGpPWpGaD
Rivastigmine—BCHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—urinary bladder cancer	0.000751	0.0184	CbGpPWpGaD
Rivastigmine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000675	0.0166	CbGpPWpGaD
Rivastigmine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00058	0.0142	CbGpPWpGaD
Rivastigmine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000564	0.0138	CbGpPWpGaD
Rivastigmine—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000556	0.0136	CbGpPWpGaD
Rivastigmine—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000457	0.0112	CbGpPWpGaD
Rivastigmine—BCHE—prostate gland—urinary bladder cancer	0.000449	0.0837	CbGeAlD
Rivastigmine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000414	0.0102	CbGpPWpGaD
Rivastigmine—ACHE—ATF-2 transcription factor network—PLAU—urinary bladder cancer	0.000382	0.00937	CbGpPWpGaD
Rivastigmine—BCHE—seminal vesicle—urinary bladder cancer	0.00038	0.0708	CbGeAlD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000379	0.00931	CbGpPWpGaD
Rivastigmine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000368	0.00904	CbGpPWpGaD
Rivastigmine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000364	0.00892	CbGpPWpGaD
Rivastigmine—ACHE—ATF-2 transcription factor network—CDK4—urinary bladder cancer	0.000361	0.00885	CbGpPWpGaD
Rivastigmine—ACHE—ATF-2 transcription factor network—ESR1—urinary bladder cancer	0.000359	0.00882	CbGpPWpGaD
Rivastigmine—BCHE—smooth muscle tissue—urinary bladder cancer	0.000318	0.0592	CbGeAlD
Rivastigmine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000317	0.00778	CbGpPWpGaD
Rivastigmine—ACHE—ATF-2 transcription factor network—RB1—urinary bladder cancer	0.000314	0.0077	CbGpPWpGaD
Rivastigmine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000311	0.00762	CbGpPWpGaD
Rivastigmine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000307	0.00752	CbGpPWpGaD
Rivastigmine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000299	0.00733	CbGpPWpGaD
Rivastigmine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000298	0.0073	CbGpPWpGaD
Rivastigmine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000295	0.00723	CbGpPWpGaD
Rivastigmine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000295	0.00723	CbGpPWpGaD
Rivastigmine—ACHE—lymph node—urinary bladder cancer	0.000292	0.0543	CbGeAlD
Rivastigmine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000291	0.00713	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000289	0.0071	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000288	0.00705	CbGpPWpGaD
Rivastigmine—ACHE—Monoamine Transport—TNF—urinary bladder cancer	0.000284	0.00697	CbGpPWpGaD
Rivastigmine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.00027	0.00661	CbGpPWpGaD
Rivastigmine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000266	0.00652	CbGpPWpGaD
Rivastigmine—ACHE—ATF-2 transcription factor network—CXCL8—urinary bladder cancer	0.00025	0.00614	CbGpPWpGaD
Rivastigmine—BCHE—female reproductive system—urinary bladder cancer	0.000245	0.0457	CbGeAlD
Rivastigmine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000243	0.00595	CbGpPWpGaD
Rivastigmine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000239	0.00587	CbGpPWpGaD
Rivastigmine—ACHE—ATF-2 transcription factor network—CCND1—urinary bladder cancer	0.000233	0.00572	CbGpPWpGaD
Rivastigmine—ACHE—Peptide hormone metabolism—IGF1—urinary bladder cancer	0.000232	0.0057	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000232	0.00568	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000227	0.00557	CbGpPWpGaD
Rivastigmine—BCHE—vagina—urinary bladder cancer	0.000222	0.0413	CbGeAlD
Rivastigmine—ACHE—ATF-2 transcription factor network—EP300—urinary bladder cancer	0.000215	0.00526	CbGpPWpGaD
Rivastigmine—BCHE—Peptide hormone metabolism—IGF1—urinary bladder cancer	0.000207	0.00508	CbGpPWpGaD
Rivastigmine—CYP3A4—renal system—urinary bladder cancer	0.000206	0.0384	CbGeAlD
Rivastigmine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000203	0.00499	CbGpPWpGaD
Rivastigmine—CYP2D6—renal system—urinary bladder cancer	0.000203	0.0378	CbGeAlD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000203	0.00497	CbGpPWpGaD
Rivastigmine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.0002	0.00492	CbGpPWpGaD
Rivastigmine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000193	0.00473	CbGpPWpGaD
Rivastigmine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000193	0.00473	CbGpPWpGaD
Rivastigmine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000191	0.000323	CcSEcCtD
Rivastigmine—Haematuria—Doxorubicin—urinary bladder cancer	0.000191	0.000322	CcSEcCtD
Rivastigmine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000191	0.000322	CcSEcCtD
Rivastigmine—Urethral disorder—Epirubicin—urinary bladder cancer	0.00019	0.000322	CcSEcCtD
Rivastigmine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00019	0.00466	CbGpPWpGaD
Rivastigmine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000189	0.00032	CcSEcCtD
Rivastigmine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000189	0.000319	CcSEcCtD
Rivastigmine—Angiopathy—Methotrexate—urinary bladder cancer	0.000188	0.000318	CcSEcCtD
Rivastigmine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000188	0.000317	CcSEcCtD
Rivastigmine—Dizziness—Fluorouracil—urinary bladder cancer	0.000187	0.000317	CcSEcCtD
Rivastigmine—Visual impairment—Epirubicin—urinary bladder cancer	0.000187	0.000316	CcSEcCtD
Rivastigmine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000187	0.000316	CcSEcCtD
Rivastigmine—Chills—Methotrexate—urinary bladder cancer	0.000186	0.000314	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000184	0.00452	CbGpPWpGaD
Rivastigmine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000184	0.00031	CcSEcCtD
Rivastigmine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000184	0.00031	CcSEcCtD
Rivastigmine—Alopecia—Methotrexate—urinary bladder cancer	0.000183	0.00031	CcSEcCtD
Rivastigmine—Vomiting—Gemcitabine—urinary bladder cancer	0.000183	0.00031	CcSEcCtD
Rivastigmine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000183	0.000309	CcSEcCtD
Rivastigmine—Mental disorder—Methotrexate—urinary bladder cancer	0.000182	0.000307	CcSEcCtD
Rivastigmine—Rash—Gemcitabine—urinary bladder cancer	0.000182	0.000307	CcSEcCtD
Rivastigmine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000181	0.000307	CcSEcCtD
Rivastigmine—Eye disorder—Epirubicin—urinary bladder cancer	0.000181	0.000307	CcSEcCtD
Rivastigmine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000181	0.000306	CcSEcCtD
Rivastigmine—Tinnitus—Epirubicin—urinary bladder cancer	0.000181	0.000306	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000181	0.00444	CbGpPWpGaD
Rivastigmine—Erythema—Methotrexate—urinary bladder cancer	0.000181	0.000305	CcSEcCtD
Rivastigmine—Malnutrition—Methotrexate—urinary bladder cancer	0.000181	0.000305	CcSEcCtD
Rivastigmine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00018	0.000305	CcSEcCtD
Rivastigmine—Headache—Gemcitabine—urinary bladder cancer	0.00018	0.000305	CcSEcCtD
Rivastigmine—Flushing—Epirubicin—urinary bladder cancer	0.00018	0.000304	CcSEcCtD
Rivastigmine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00018	0.000304	CcSEcCtD
Rivastigmine—Vomiting—Fluorouracil—urinary bladder cancer	0.00018	0.000304	CcSEcCtD
Rivastigmine—Rhinitis—Doxorubicin—urinary bladder cancer	0.00018	0.000304	CcSEcCtD
Rivastigmine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.00018	0.000303	CcSEcCtD
Rivastigmine—Hepatitis—Doxorubicin—urinary bladder cancer	0.00018	0.000303	CcSEcCtD
Rivastigmine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000179	0.000302	CcSEcCtD
Rivastigmine—Rash—Fluorouracil—urinary bladder cancer	0.000179	0.000302	CcSEcCtD
Rivastigmine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000178	0.000302	CcSEcCtD
Rivastigmine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000178	0.000301	CcSEcCtD
Rivastigmine—Headache—Fluorouracil—urinary bladder cancer	0.000177	0.0003	CcSEcCtD
Rivastigmine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000177	0.0003	CcSEcCtD
Rivastigmine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000177	0.000299	CcSEcCtD
Rivastigmine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000177	0.000299	CcSEcCtD
Rivastigmine—Asthenia—Etoposide—urinary bladder cancer	0.000176	0.000298	CcSEcCtD
Rivastigmine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000176	0.000298	CcSEcCtD
Rivastigmine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000176	0.00432	CbGpPWpGaD
Rivastigmine—Angiopathy—Epirubicin—urinary bladder cancer	0.000176	0.000298	CcSEcCtD
Rivastigmine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000176	0.000297	CcSEcCtD
Rivastigmine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000175	0.000296	CcSEcCtD
Rivastigmine—Back pain—Methotrexate—urinary bladder cancer	0.000175	0.000295	CcSEcCtD
Rivastigmine—Chills—Epirubicin—urinary bladder cancer	0.000174	0.000294	CcSEcCtD
Rivastigmine—Pruritus—Etoposide—urinary bladder cancer	0.000174	0.000294	CcSEcCtD
Rivastigmine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000174	0.00426	CbGpPWpGaD
Rivastigmine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000173	0.000293	CcSEcCtD
Rivastigmine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000173	0.000292	CcSEcCtD
Rivastigmine—Alopecia—Epirubicin—urinary bladder cancer	0.000171	0.00029	CcSEcCtD
Rivastigmine—Nausea—Gemcitabine—urinary bladder cancer	0.000171	0.000289	CcSEcCtD
Rivastigmine—Vomiting—Cisplatin—urinary bladder cancer	0.000171	0.000289	CcSEcCtD
Rivastigmine—Vision blurred—Methotrexate—urinary bladder cancer	0.00017	0.000288	CcSEcCtD
Rivastigmine—Mental disorder—Epirubicin—urinary bladder cancer	0.00017	0.000287	CcSEcCtD
Rivastigmine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00017	0.000287	CcSEcCtD
Rivastigmine—Rash—Cisplatin—urinary bladder cancer	0.000169	0.000286	CcSEcCtD
Rivastigmine—Dermatitis—Cisplatin—urinary bladder cancer	0.000169	0.000286	CcSEcCtD
Rivastigmine—Malnutrition—Epirubicin—urinary bladder cancer	0.000169	0.000286	CcSEcCtD
Rivastigmine—Erythema—Epirubicin—urinary bladder cancer	0.000169	0.000286	CcSEcCtD
Rivastigmine—Diarrhoea—Etoposide—urinary bladder cancer	0.000168	0.000284	CcSEcCtD
Rivastigmine—Nausea—Fluorouracil—urinary bladder cancer	0.000168	0.000284	CcSEcCtD
Rivastigmine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000168	0.000284	CcSEcCtD
Rivastigmine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000168	0.000283	CcSEcCtD
Rivastigmine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000167	0.000283	CcSEcCtD
Rivastigmine—Anaemia—Methotrexate—urinary bladder cancer	0.000167	0.000282	CcSEcCtD
Rivastigmine—Flushing—Doxorubicin—urinary bladder cancer	0.000167	0.000282	CcSEcCtD
Rivastigmine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000167	0.000282	CcSEcCtD
Rivastigmine—Flatulence—Epirubicin—urinary bladder cancer	0.000166	0.000281	CcSEcCtD
Rivastigmine—Tension—Epirubicin—urinary bladder cancer	0.000166	0.00028	CcSEcCtD
Rivastigmine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000165	0.00028	CcSEcCtD
Rivastigmine—ACHE—Metabolism of proteins—CDX2—urinary bladder cancer	0.000165	0.00405	CbGpPWpGaD
Rivastigmine—CYP3A4—female reproductive system—urinary bladder cancer	0.000165	0.0307	CbGeAlD
Rivastigmine—Nervousness—Epirubicin—urinary bladder cancer	0.000164	0.000277	CcSEcCtD
Rivastigmine—Back pain—Epirubicin—urinary bladder cancer	0.000163	0.000276	CcSEcCtD
Rivastigmine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000163	0.000275	CcSEcCtD
Rivastigmine—Malaise—Methotrexate—urinary bladder cancer	0.000163	0.000275	CcSEcCtD
Rivastigmine—Dizziness—Etoposide—urinary bladder cancer	0.000163	0.000275	CcSEcCtD
Rivastigmine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000162	0.000275	CcSEcCtD
Rivastigmine—CYP2D6—female reproductive system—urinary bladder cancer	0.000162	0.0303	CbGeAlD
Rivastigmine—Vertigo—Methotrexate—urinary bladder cancer	0.000162	0.000274	CcSEcCtD
Rivastigmine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000162	0.000274	CcSEcCtD
Rivastigmine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000161	0.00396	CbGpPWpGaD
Rivastigmine—Chills—Doxorubicin—urinary bladder cancer	0.000161	0.000272	CcSEcCtD
Rivastigmine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00016	0.000271	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.00016	0.00393	CbGpPWpGaD
Rivastigmine—Nausea—Cisplatin—urinary bladder cancer	0.000159	0.00027	CcSEcCtD
Rivastigmine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000159	0.00391	CbGpPWpGaD
Rivastigmine—Vision blurred—Epirubicin—urinary bladder cancer	0.000159	0.000269	CcSEcCtD
Rivastigmine—Alopecia—Doxorubicin—urinary bladder cancer	0.000159	0.000268	CcSEcCtD
Rivastigmine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000159	0.00389	CbGpPWpGaD
Rivastigmine—Cough—Methotrexate—urinary bladder cancer	0.000158	0.000266	CcSEcCtD
Rivastigmine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000157	0.000266	CcSEcCtD
Rivastigmine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000157	0.000265	CcSEcCtD
Rivastigmine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000156	0.00384	CbGpPWpGaD
Rivastigmine—Convulsion—Methotrexate—urinary bladder cancer	0.000156	0.000264	CcSEcCtD
Rivastigmine—Vomiting—Etoposide—urinary bladder cancer	0.000156	0.000264	CcSEcCtD
Rivastigmine—Erythema—Doxorubicin—urinary bladder cancer	0.000156	0.000264	CcSEcCtD
Rivastigmine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000156	0.000264	CcSEcCtD
Rivastigmine—Anaemia—Epirubicin—urinary bladder cancer	0.000156	0.000264	CcSEcCtD
Rivastigmine—Agitation—Epirubicin—urinary bladder cancer	0.000155	0.000262	CcSEcCtD
Rivastigmine—Rash—Etoposide—urinary bladder cancer	0.000155	0.000262	CcSEcCtD
Rivastigmine—Dermatitis—Etoposide—urinary bladder cancer	0.000155	0.000262	CcSEcCtD
Rivastigmine—Headache—Etoposide—urinary bladder cancer	0.000154	0.00026	CcSEcCtD
Rivastigmine—Flatulence—Doxorubicin—urinary bladder cancer	0.000154	0.00026	CcSEcCtD
Rivastigmine—Myalgia—Methotrexate—urinary bladder cancer	0.000154	0.00026	CcSEcCtD
Rivastigmine—Arthralgia—Methotrexate—urinary bladder cancer	0.000154	0.00026	CcSEcCtD
Rivastigmine—Chest pain—Methotrexate—urinary bladder cancer	0.000154	0.00026	CcSEcCtD
Rivastigmine—Tension—Doxorubicin—urinary bladder cancer	0.000153	0.000259	CcSEcCtD
Rivastigmine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000153	0.000259	CcSEcCtD
Rivastigmine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000153	0.000258	CcSEcCtD
Rivastigmine—Malaise—Epirubicin—urinary bladder cancer	0.000152	0.000257	CcSEcCtD
Rivastigmine—Discomfort—Methotrexate—urinary bladder cancer	0.000152	0.000257	CcSEcCtD
Rivastigmine—Nervousness—Doxorubicin—urinary bladder cancer	0.000152	0.000257	CcSEcCtD
Rivastigmine—Vertigo—Epirubicin—urinary bladder cancer	0.000152	0.000257	CcSEcCtD
Rivastigmine—Syncope—Epirubicin—urinary bladder cancer	0.000152	0.000256	CcSEcCtD
Rivastigmine—Back pain—Doxorubicin—urinary bladder cancer	0.000151	0.000256	CcSEcCtD
Rivastigmine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.00015	0.000254	CcSEcCtD
Rivastigmine—Palpitations—Epirubicin—urinary bladder cancer	0.000149	0.000252	CcSEcCtD
Rivastigmine—Confusional state—Methotrexate—urinary bladder cancer	0.000149	0.000251	CcSEcCtD
Rivastigmine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000148	0.000251	CcSEcCtD
Rivastigmine—Cough—Epirubicin—urinary bladder cancer	0.000147	0.000249	CcSEcCtD
Rivastigmine—BCHE—Metabolism of proteins—CDX2—urinary bladder cancer	0.000147	0.00362	CbGpPWpGaD
Rivastigmine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000147	0.000249	CcSEcCtD
Rivastigmine—Convulsion—Epirubicin—urinary bladder cancer	0.000146	0.000247	CcSEcCtD
Rivastigmine—Infection—Methotrexate—urinary bladder cancer	0.000146	0.000247	CcSEcCtD
Rivastigmine—Nausea—Etoposide—urinary bladder cancer	0.000146	0.000247	CcSEcCtD
Rivastigmine—Hypertension—Epirubicin—urinary bladder cancer	0.000146	0.000247	CcSEcCtD
Rivastigmine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000145	0.000245	CcSEcCtD
Rivastigmine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000144	0.000244	CcSEcCtD
Rivastigmine—Anaemia—Doxorubicin—urinary bladder cancer	0.000144	0.000244	CcSEcCtD
Rivastigmine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000144	0.000244	CcSEcCtD
Rivastigmine—Myalgia—Epirubicin—urinary bladder cancer	0.000144	0.000243	CcSEcCtD
Rivastigmine—Arthralgia—Epirubicin—urinary bladder cancer	0.000144	0.000243	CcSEcCtD
Rivastigmine—Chest pain—Epirubicin—urinary bladder cancer	0.000144	0.000243	CcSEcCtD
Rivastigmine—Agitation—Doxorubicin—urinary bladder cancer	0.000144	0.000243	CcSEcCtD
Rivastigmine—BCHE—lymph node—urinary bladder cancer	0.000143	0.0267	CbGeAlD
Rivastigmine—Anxiety—Epirubicin—urinary bladder cancer	0.000143	0.000242	CcSEcCtD
Rivastigmine—Skin disorder—Methotrexate—urinary bladder cancer	0.000143	0.000242	CcSEcCtD
Rivastigmine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000143	0.000241	CcSEcCtD
Rivastigmine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000142	0.000241	CcSEcCtD
Rivastigmine—Discomfort—Epirubicin—urinary bladder cancer	0.000142	0.00024	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000142	0.00347	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000141	0.00346	CbGpPWpGaD
Rivastigmine—Malaise—Doxorubicin—urinary bladder cancer	0.000141	0.000238	CcSEcCtD
Rivastigmine—Dry mouth—Epirubicin—urinary bladder cancer	0.000141	0.000238	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.00014	0.00344	CbGpPWpGaD
Rivastigmine—Vertigo—Doxorubicin—urinary bladder cancer	0.00014	0.000237	CcSEcCtD
Rivastigmine—Anorexia—Methotrexate—urinary bladder cancer	0.00014	0.000237	CcSEcCtD
Rivastigmine—Syncope—Doxorubicin—urinary bladder cancer	0.00014	0.000237	CcSEcCtD
Rivastigmine—Confusional state—Epirubicin—urinary bladder cancer	0.000139	0.000235	CcSEcCtD
Rivastigmine—Palpitations—Doxorubicin—urinary bladder cancer	0.000138	0.000233	CcSEcCtD
Rivastigmine—Oedema—Epirubicin—urinary bladder cancer	0.000138	0.000233	CcSEcCtD
Rivastigmine—Hypotension—Methotrexate—urinary bladder cancer	0.000138	0.000233	CcSEcCtD
Rivastigmine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000137	0.000232	CcSEcCtD
Rivastigmine—Infection—Epirubicin—urinary bladder cancer	0.000137	0.000231	CcSEcCtD
Rivastigmine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000137	0.00335	CbGpPWpGaD
Rivastigmine—Cough—Doxorubicin—urinary bladder cancer	0.000136	0.000231	CcSEcCtD
Rivastigmine—Shock—Epirubicin—urinary bladder cancer	0.000136	0.000229	CcSEcCtD
Rivastigmine—Convulsion—Doxorubicin—urinary bladder cancer	0.000135	0.000229	CcSEcCtD
Rivastigmine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000135	0.000229	CcSEcCtD
Rivastigmine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000135	0.000228	CcSEcCtD
Rivastigmine—Hypertension—Doxorubicin—urinary bladder cancer	0.000135	0.000228	CcSEcCtD
Rivastigmine—Tachycardia—Epirubicin—urinary bladder cancer	0.000135	0.000227	CcSEcCtD
Rivastigmine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000134	0.000227	CcSEcCtD
Rivastigmine—Skin disorder—Epirubicin—urinary bladder cancer	0.000134	0.000226	CcSEcCtD
Rivastigmine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000133	0.000225	CcSEcCtD
Rivastigmine—Insomnia—Methotrexate—urinary bladder cancer	0.000133	0.000225	CcSEcCtD
Rivastigmine—Myalgia—Doxorubicin—urinary bladder cancer	0.000133	0.000225	CcSEcCtD
Rivastigmine—Chest pain—Doxorubicin—urinary bladder cancer	0.000133	0.000225	CcSEcCtD
Rivastigmine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000133	0.000225	CcSEcCtD
Rivastigmine—Anxiety—Doxorubicin—urinary bladder cancer	0.000133	0.000224	CcSEcCtD
Rivastigmine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000132	0.000224	CcSEcCtD
Rivastigmine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000132	0.000223	CcSEcCtD
Rivastigmine—Discomfort—Doxorubicin—urinary bladder cancer	0.000131	0.000222	CcSEcCtD
Rivastigmine—Anorexia—Epirubicin—urinary bladder cancer	0.000131	0.000222	CcSEcCtD
Rivastigmine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000131	0.000222	CcSEcCtD
Rivastigmine—Somnolence—Methotrexate—urinary bladder cancer	0.000131	0.000221	CcSEcCtD
Rivastigmine—Dry mouth—Doxorubicin—urinary bladder cancer	0.00013	0.00022	CcSEcCtD
Rivastigmine—Dyspepsia—Methotrexate—urinary bladder cancer	0.00013	0.000219	CcSEcCtD
Rivastigmine—ACHE—Metabolism—GSTZ1—urinary bladder cancer	0.00013	0.00318	CbGpPWpGaD
Rivastigmine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000129	0.00317	CbGpPWpGaD
Rivastigmine—Hypotension—Epirubicin—urinary bladder cancer	0.000129	0.000218	CcSEcCtD
Rivastigmine—Confusional state—Doxorubicin—urinary bladder cancer	0.000129	0.000217	CcSEcCtD
Rivastigmine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000128	0.000216	CcSEcCtD
Rivastigmine—Oedema—Doxorubicin—urinary bladder cancer	0.000128	0.000216	CcSEcCtD
Rivastigmine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000127	0.000215	CcSEcCtD
Rivastigmine—Fatigue—Methotrexate—urinary bladder cancer	0.000127	0.000215	CcSEcCtD
Rivastigmine—Infection—Doxorubicin—urinary bladder cancer	0.000127	0.000214	CcSEcCtD
Rivastigmine—Pain—Methotrexate—urinary bladder cancer	0.000126	0.000213	CcSEcCtD
Rivastigmine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000126	0.000212	CcSEcCtD
Rivastigmine—Shock—Doxorubicin—urinary bladder cancer	0.000126	0.000212	CcSEcCtD
Rivastigmine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000125	0.00307	CbGpPWpGaD
Rivastigmine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000125	0.000211	CcSEcCtD
Rivastigmine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000125	0.000211	CcSEcCtD
Rivastigmine—Insomnia—Epirubicin—urinary bladder cancer	0.000125	0.000211	CcSEcCtD
Rivastigmine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000125	0.00021	CcSEcCtD
Rivastigmine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000209	CcSEcCtD
Rivastigmine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000124	0.000209	CcSEcCtD
Rivastigmine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000123	0.000208	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000123	0.00302	CbGpPWpGaD
Rivastigmine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000123	0.000208	CcSEcCtD
Rivastigmine—ACHE—Metabolism—GSTO2—urinary bladder cancer	0.000123	0.00301	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—NAT1—urinary bladder cancer	0.000123	0.00301	CbGpPWpGaD
Rivastigmine—Somnolence—Epirubicin—urinary bladder cancer	0.000123	0.000207	CcSEcCtD
Rivastigmine—Anorexia—Doxorubicin—urinary bladder cancer	0.000122	0.000206	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000122	0.00298	CbGpPWpGaD
Rivastigmine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000121	0.000205	CcSEcCtD
Rivastigmine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000121	0.000205	CcSEcCtD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000121	0.00296	CbGpPWpGaD
Rivastigmine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00012	0.000204	CcSEcCtD
Rivastigmine—Decreased appetite—Epirubicin—urinary bladder cancer	0.00012	0.000203	CcSEcCtD
Rivastigmine—Hypotension—Doxorubicin—urinary bladder cancer	0.000119	0.000201	CcSEcCtD
Rivastigmine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000119	0.000201	CcSEcCtD
Rivastigmine—Fatigue—Epirubicin—urinary bladder cancer	0.000119	0.000201	CcSEcCtD
Rivastigmine—Pain—Epirubicin—urinary bladder cancer	0.000118	0.000199	CcSEcCtD
Rivastigmine—Constipation—Epirubicin—urinary bladder cancer	0.000118	0.000199	CcSEcCtD
Rivastigmine—Urticaria—Methotrexate—urinary bladder cancer	0.000117	0.000198	CcSEcCtD
Rivastigmine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000116	0.000197	CcSEcCtD
Rivastigmine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000116	0.000197	CcSEcCtD
Rivastigmine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000116	0.000196	CcSEcCtD
Rivastigmine—BCHE—Metabolism—GSTZ1—urinary bladder cancer	0.000116	0.00284	CbGpPWpGaD
Rivastigmine—Insomnia—Doxorubicin—urinary bladder cancer	0.000115	0.000195	CcSEcCtD
Rivastigmine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000115	0.000194	CcSEcCtD
Rivastigmine—ACHE—Phospholipid metabolism—PTEN—urinary bladder cancer	0.000114	0.0028	CbGpPWpGaD
Rivastigmine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000114	0.000192	CcSEcCtD
Rivastigmine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000114	0.000192	CcSEcCtD
Rivastigmine—Somnolence—Doxorubicin—urinary bladder cancer	0.000113	0.000192	CcSEcCtD
Rivastigmine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000113	0.000191	CcSEcCtD
Rivastigmine—ACHE—Metabolism—UGT2B7—urinary bladder cancer	0.000112	0.00276	CbGpPWpGaD
Rivastigmine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000112	0.00019	CcSEcCtD
Rivastigmine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000111	0.000187	CcSEcCtD
Rivastigmine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00011	0.000186	CcSEcCtD
Rivastigmine—Fatigue—Doxorubicin—urinary bladder cancer	0.00011	0.000186	CcSEcCtD
Rivastigmine—BCHE—Metabolism—GSTO2—urinary bladder cancer	0.00011	0.00269	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—NAT1—urinary bladder cancer	0.00011	0.00269	CbGpPWpGaD
Rivastigmine—Urticaria—Epirubicin—urinary bladder cancer	0.00011	0.000185	CcSEcCtD
Rivastigmine—Pain—Doxorubicin—urinary bladder cancer	0.000109	0.000184	CcSEcCtD
Rivastigmine—Constipation—Doxorubicin—urinary bladder cancer	0.000109	0.000184	CcSEcCtD
Rivastigmine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000109	0.000184	CcSEcCtD
Rivastigmine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000109	0.000184	CcSEcCtD
Rivastigmine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000109	0.000183	CcSEcCtD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000108	0.00264	CbGpPWpGaD
Rivastigmine—Asthenia—Methotrexate—urinary bladder cancer	0.000106	0.000179	CcSEcCtD
Rivastigmine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000106	0.00259	CbGpPWpGaD
Rivastigmine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000105	0.000178	CcSEcCtD
Rivastigmine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000104	0.000176	CcSEcCtD
Rivastigmine—Pruritus—Methotrexate—urinary bladder cancer	0.000104	0.000176	CcSEcCtD
Rivastigmine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000104	0.00255	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of proteins—IGFBP3—urinary bladder cancer	0.000104	0.00255	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000103	0.00253	CbGpPWpGaD
Rivastigmine—BCHE—Phospholipid metabolism—PTEN—urinary bladder cancer	0.000102	0.00249	CbGpPWpGaD
Rivastigmine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000102	0.000172	CcSEcCtD
Rivastigmine—Urticaria—Doxorubicin—urinary bladder cancer	0.000101	0.000171	CcSEcCtD
Rivastigmine—ACHE—Metabolism—CYP4B1—urinary bladder cancer	0.000101	0.00248	CbGpPWpGaD
Rivastigmine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000101	0.00017	CcSEcCtD
Rivastigmine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000101	0.00017	CcSEcCtD
Rivastigmine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000101	0.00017	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000101	0.00247	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—UGT2B7—urinary bladder cancer	0.0001	0.00246	CbGpPWpGaD
Rivastigmine—Asthenia—Epirubicin—urinary bladder cancer	9.89e-05	0.000167	CcSEcCtD
Rivastigmine—Pruritus—Epirubicin—urinary bladder cancer	9.76e-05	0.000165	CcSEcCtD
Rivastigmine—Dizziness—Methotrexate—urinary bladder cancer	9.74e-05	0.000165	CcSEcCtD
Rivastigmine—ACHE—Metabolism—SLC19A1—urinary bladder cancer	9.56e-05	0.00234	CbGpPWpGaD
Rivastigmine—Diarrhoea—Epirubicin—urinary bladder cancer	9.43e-05	0.000159	CcSEcCtD
Rivastigmine—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.4e-05	0.000159	CcSEcCtD
Rivastigmine—Vomiting—Methotrexate—urinary bladder cancer	9.37e-05	0.000158	CcSEcCtD
Rivastigmine—ACHE—Metabolism—PRSS3—urinary bladder cancer	9.31e-05	0.00228	CbGpPWpGaD
Rivastigmine—Rash—Methotrexate—urinary bladder cancer	9.29e-05	0.000157	CcSEcCtD
Rivastigmine—Dermatitis—Methotrexate—urinary bladder cancer	9.28e-05	0.000157	CcSEcCtD
Rivastigmine—BCHE—Metabolism of proteins—IGFBP3—urinary bladder cancer	9.26e-05	0.00227	CbGpPWpGaD
Rivastigmine—Headache—Methotrexate—urinary bladder cancer	9.23e-05	0.000156	CcSEcCtD
Rivastigmine—Asthenia—Doxorubicin—urinary bladder cancer	9.15e-05	0.000155	CcSEcCtD
Rivastigmine—Dizziness—Epirubicin—urinary bladder cancer	9.12e-05	0.000154	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	9.11e-05	0.00223	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—CYP4B1—urinary bladder cancer	9.03e-05	0.00221	CbGpPWpGaD
Rivastigmine—Pruritus—Doxorubicin—urinary bladder cancer	9.03e-05	0.000153	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	8.81e-05	0.00216	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	8.79e-05	0.00216	CbGpPWpGaD
Rivastigmine—Vomiting—Epirubicin—urinary bladder cancer	8.77e-05	0.000148	CcSEcCtD
Rivastigmine—Nausea—Methotrexate—urinary bladder cancer	8.75e-05	0.000148	CcSEcCtD
Rivastigmine—Diarrhoea—Doxorubicin—urinary bladder cancer	8.73e-05	0.000148	CcSEcCtD
Rivastigmine—Rash—Epirubicin—urinary bladder cancer	8.69e-05	0.000147	CcSEcCtD
Rivastigmine—Dermatitis—Epirubicin—urinary bladder cancer	8.69e-05	0.000147	CcSEcCtD
Rivastigmine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	8.68e-05	0.00213	CbGpPWpGaD
Rivastigmine—Headache—Epirubicin—urinary bladder cancer	8.64e-05	0.000146	CcSEcCtD
Rivastigmine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.56e-05	0.0021	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—SLC19A1—urinary bladder cancer	8.52e-05	0.00209	CbGpPWpGaD
Rivastigmine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	8.44e-05	0.00207	CbGpPWpGaD
Rivastigmine—Dizziness—Doxorubicin—urinary bladder cancer	8.44e-05	0.000143	CcSEcCtD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	8.38e-05	0.00206	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—PRSS3—urinary bladder cancer	8.31e-05	0.00204	CbGpPWpGaD
Rivastigmine—Nausea—Epirubicin—urinary bladder cancer	8.19e-05	0.000138	CcSEcCtD
Rivastigmine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	8.19e-05	0.00201	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	8.15e-05	0.002	CbGpPWpGaD
Rivastigmine—Vomiting—Doxorubicin—urinary bladder cancer	8.11e-05	0.000137	CcSEcCtD
Rivastigmine—Rash—Doxorubicin—urinary bladder cancer	8.04e-05	0.000136	CcSEcCtD
Rivastigmine—Dermatitis—Doxorubicin—urinary bladder cancer	8.04e-05	0.000136	CcSEcCtD
Rivastigmine—Headache—Doxorubicin—urinary bladder cancer	7.99e-05	0.000135	CcSEcCtD
Rivastigmine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	7.98e-05	0.00196	CbGpPWpGaD
Rivastigmine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.87e-05	0.00193	CbGpPWpGaD
Rivastigmine—Nausea—Doxorubicin—urinary bladder cancer	7.58e-05	0.000128	CcSEcCtD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.47e-05	0.00183	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—TYMP—urinary bladder cancer	7.44e-05	0.00183	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	7.31e-05	0.00179	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.15e-05	0.00175	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.15e-05	0.00175	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	6.81e-05	0.00167	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	6.75e-05	0.00166	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—NAT2—urinary bladder cancer	6.73e-05	0.00165	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.66e-05	0.00163	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—TYMP—urinary bladder cancer	6.64e-05	0.00163	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.38e-05	0.00156	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—NAT2—urinary bladder cancer	6.01e-05	0.00147	CbGpPWpGaD
Rivastigmine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6e-05	0.00147	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—RRM2—urinary bladder cancer	5.81e-05	0.00143	CbGpPWpGaD
Rivastigmine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.67e-05	0.00139	CbGpPWpGaD
Rivastigmine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.6e-05	0.00137	CbGpPWpGaD
Rivastigmine—ACHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.53e-05	0.00136	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—HPGDS—urinary bladder cancer	5.38e-05	0.00132	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—ENO2—urinary bladder cancer	5.38e-05	0.00132	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.35e-05	0.00131	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	5.32e-05	0.0013	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—GSTT1—urinary bladder cancer	5.22e-05	0.00128	CbGpPWpGaD
Rivastigmine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.21e-05	0.00128	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—RRM2—urinary bladder cancer	5.18e-05	0.00127	CbGpPWpGaD
Rivastigmine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.14e-05	0.00126	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.14e-05	0.00126	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	5.04e-05	0.00124	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	5.04e-05	0.00124	CbGpPWpGaD
Rivastigmine—BCHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.93e-05	0.00121	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—ENO2—urinary bladder cancer	4.8e-05	0.00118	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—HPGDS—urinary bladder cancer	4.8e-05	0.00118	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.77e-05	0.00117	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—GSTT1—urinary bladder cancer	4.66e-05	0.00114	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	4.61e-05	0.00113	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.59e-05	0.00112	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of proteins—IGF1—urinary bladder cancer	4.39e-05	0.00108	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—NQO1—urinary bladder cancer	4.34e-05	0.00106	CbGpPWpGaD
Rivastigmine—ACHE—Neuronal System—HRAS—urinary bladder cancer	4.24e-05	0.00104	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.21e-05	0.00103	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	4.15e-05	0.00102	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	3.92e-05	0.000961	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of proteins—IGF1—urinary bladder cancer	3.91e-05	0.00096	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—NQO1—urinary bladder cancer	3.87e-05	0.000949	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	3.82e-05	0.000937	CbGpPWpGaD
Rivastigmine—BCHE—Neuronal System—HRAS—urinary bladder cancer	3.78e-05	0.000927	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.76e-05	0.000921	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.67e-05	0.0009	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—GSTP1—urinary bladder cancer	3.62e-05	0.000887	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of proteins—CXCL8—urinary bladder cancer	3.53e-05	0.000865	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.5e-05	0.000859	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.48e-05	0.000853	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—TYMS—urinary bladder cancer	3.36e-05	0.000825	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—NCOR1—urinary bladder cancer	3.33e-05	0.000816	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—GSTM1—urinary bladder cancer	3.33e-05	0.000816	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.3e-05	0.000808	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.3e-05	0.000808	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.27e-05	0.000803	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—GSTP1—urinary bladder cancer	3.23e-05	0.000792	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—GPX1—urinary bladder cancer	3.18e-05	0.000781	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of proteins—CXCL8—urinary bladder cancer	3.15e-05	0.000772	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—ERCC2—urinary bladder cancer	3.13e-05	0.000767	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.12e-05	0.000766	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	3.05e-05	0.000749	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.01e-05	0.000739	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—TYMS—urinary bladder cancer	3e-05	0.000736	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—NCOR1—urinary bladder cancer	2.97e-05	0.000728	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—GSTM1—urinary bladder cancer	2.97e-05	0.000728	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—MTHFR—urinary bladder cancer	2.94e-05	0.000721	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—GPX1—urinary bladder cancer	2.84e-05	0.000697	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—ERCC2—urinary bladder cancer	2.79e-05	0.000684	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	2.76e-05	0.000677	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.71e-05	0.000666	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—MTHFR—urinary bladder cancer	2.62e-05	0.000643	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.56e-05	0.000629	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.5e-05	0.000612	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	2.38e-05	0.000585	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—PPARG—urinary bladder cancer	2.38e-05	0.000584	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—CREBBP—urinary bladder cancer	2.29e-05	0.000561	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.21e-05	0.000541	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.21e-05	0.000541	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.14e-05	0.000525	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—PPARG—urinary bladder cancer	2.13e-05	0.000521	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—CREBBP—urinary bladder cancer	2.04e-05	0.000501	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2e-05	0.00049	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—PTGS2—urinary bladder cancer	1.87e-05	0.00046	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.81e-05	0.000443	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.78e-05	0.000436	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—PTGS2—urinary bladder cancer	1.67e-05	0.00041	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—PTEN—urinary bladder cancer	1.63e-05	0.000401	CbGpPWpGaD
Rivastigmine—ACHE—Metabolism—EP300—urinary bladder cancer	1.56e-05	0.000382	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.56e-05	0.000382	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.48e-05	0.000364	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—PTEN—urinary bladder cancer	1.46e-05	0.000358	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.44e-05	0.000354	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.44e-05	0.000354	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.4e-05	0.000343	CbGpPWpGaD
Rivastigmine—BCHE—Metabolism—EP300—urinary bladder cancer	1.39e-05	0.000341	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.38e-05	0.000338	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.36e-05	0.000335	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.36e-05	0.000335	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.31e-05	0.00032	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.28e-05	0.000315	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.21e-05	0.000296	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.16e-05	0.000285	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9.77e-06	0.00024	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.7e-06	0.000238	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	9.39e-06	0.00023	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	9.02e-06	0.000221	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.92e-06	0.000219	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.92e-06	0.000219	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.54e-06	0.000209	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.38e-06	0.000206	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.88e-06	0.000193	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.69e-06	0.000189	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.71e-06	0.000164	CbGpPWpGaD
Rivastigmine—CYP2D6—Metabolism—EP300—urinary bladder cancer	6.39e-06	0.000157	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.39e-06	0.000157	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.14e-06	0.000151	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.03e-06	0.000123	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.38e-06	0.000108	CbGpPWpGaD
Rivastigmine—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.18e-06	0.000103	CbGpPWpGaD
